Villejuif-Grand Paris, France, January 16, 2023 – EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces that a first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax® AK in lung and kidney cancer patients. The aim of the trial is to assess the […]
